JP2022088411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022088411A5 JP2022088411A5 JP2022034413A JP2022034413A JP2022088411A5 JP 2022088411 A5 JP2022088411 A5 JP 2022088411A5 JP 2022034413 A JP2022034413 A JP 2022034413A JP 2022034413 A JP2022034413 A JP 2022034413A JP 2022088411 A5 JP2022088411 A5 JP 2022088411A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061724A JP2023093549A (ja) | 2018-03-02 | 2023-04-05 | Ｐｄ－１アゴニスト抗体およびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637643P | 2018-03-02 | 2018-03-02 | |
| US62/637,643 | 2018-03-02 | ||
| PCT/US2019/019076 WO2019168745A1 (en) | 2018-03-02 | 2019-02-22 | Pd-1 agonist antibodies and uses thereof |
| JP2020545727A JP7071521B2 (ja) | 2018-03-02 | 2019-02-22 | Ｐｄ－１アゴニスト抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545727A Division JP7071521B2 (ja) | 2018-03-02 | 2019-02-22 | Ｐｄ－１アゴニスト抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061724A Division JP2023093549A (ja) | 2018-03-02 | 2023-04-05 | Ｐｄ－１アゴニスト抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022088411A JP2022088411A (ja) | 2022-06-14 |
| JP2022088411A5 true JP2022088411A5 (https=) | 2023-01-06 |
| JP7259107B2 JP7259107B2 (ja) | 2023-04-17 |
Family
ID=65686121
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545727A Active JP7071521B2 (ja) | 2018-03-02 | 2019-02-22 | Ｐｄ－１アゴニスト抗体およびその使用 |
| JP2022034413A Active JP7259107B2 (ja) | 2018-03-02 | 2022-03-07 | Ｐｄ－１アゴニスト抗体およびその使用 |
| JP2023061724A Pending JP2023093549A (ja) | 2018-03-02 | 2023-04-05 | Ｐｄ－１アゴニスト抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545727A Active JP7071521B2 (ja) | 2018-03-02 | 2019-02-22 | Ｐｄ－１アゴニスト抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061724A Pending JP2023093549A (ja) | 2018-03-02 | 2023-04-05 | Ｐｄ－１アゴニスト抗体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10493148B2 (https=) |
| EP (1) | EP3759139A1 (https=) |
| JP (3) | JP7071521B2 (https=) |
| KR (2) | KR102536014B1 (https=) |
| CN (4) | CN111886253B (https=) |
| AR (1) | AR114127A1 (https=) |
| AU (2) | AU2019228474B2 (https=) |
| BR (1) | BR112020015983A2 (https=) |
| CA (1) | CA3092064C (https=) |
| CL (1) | CL2020002180A1 (https=) |
| CO (1) | CO2020010188A2 (https=) |
| CR (1) | CR20200375A (https=) |
| DO (1) | DOP2020000153A (https=) |
| EA (1) | EA202091809A1 (https=) |
| EC (1) | ECSP20053544A (https=) |
| IL (1) | IL276340A (https=) |
| JO (1) | JOP20200210A1 (https=) |
| MA (1) | MA52414A (https=) |
| MX (1) | MX2020009124A (https=) |
| PE (1) | PE20210045A1 (https=) |
| PH (1) | PH12020551463A1 (https=) |
| SA (1) | SA520420082B1 (https=) |
| SG (1) | SG11202008437WA (https=) |
| TW (1) | TWI708787B (https=) |
| WO (1) | WO2019168745A1 (https=) |
| ZA (1) | ZA202004601B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| CN116333126A (zh) * | 2018-03-20 | 2023-06-27 | 上海药明生物技术有限公司 | 新型抗pd-1抗体 |
| WO2020231882A2 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| EP4107189A4 (en) * | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS |
| BR112022021392A2 (pt) * | 2020-04-22 | 2022-12-06 | Igm Biosciences Inc | Moléculas de ligação multiméricas de agonista de pd-1 |
| EP4159235A4 (en) * | 2020-05-25 | 2024-07-10 | Foundation for Biomedical Research and Innovation at Kobe | PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE |
| BR112022023989A2 (pt) | 2020-05-26 | 2023-02-07 | Boehringer Ingelheim Int | Anticorpos anti-pd-1 |
| IL307887A (en) | 2021-05-13 | 2023-12-01 | Foundation For Biomedical Res And Innovation At Kobe | Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases |
| PE20241755A1 (es) | 2021-11-19 | 2024-08-28 | Mirobio Ltd | Anticuerpos pd-1 disenados por ingenieria y usos de estos |
| JP2025504020A (ja) * | 2022-01-28 | 2025-02-06 | ジョージアミューン・インコーポレイテッド | Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体 |
| WO2023200796A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Immune cell inhibition by immune checkpoint engagers |
| WO2024010861A2 (en) * | 2022-07-06 | 2024-01-11 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| WO2024040206A2 (en) * | 2022-08-19 | 2024-02-22 | Eli Lilly And Company | Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody |
| WO2024050421A2 (en) * | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
| WO2024092031A1 (en) | 2022-10-25 | 2024-05-02 | Seismic Therapeutic, Inc. | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
| TW202500583A (zh) * | 2023-03-17 | 2025-01-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法 |
| WO2025042732A1 (en) * | 2023-08-18 | 2025-02-27 | Eli Lilly And Company | Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody |
| CN120424213A (zh) * | 2024-02-02 | 2025-08-05 | 英诺湖医药(杭州)有限公司 | 特异性结合pd-1的单克隆抗体及其医药用途 |
| WO2026008664A1 (en) | 2024-07-01 | 2026-01-08 | Vib Vzw | Allosteric modulators of inhibitory immune receptor complexes |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2742953B1 (en) * | 2011-08-11 | 2021-09-22 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| CN105431449B (zh) | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | 新的pd1同种型及其用于加强免疫应答的用途 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| WO2016020856A2 (en) * | 2014-08-05 | 2016-02-11 | MabQuest SA | Immunological reagents |
| HK1254803A1 (zh) | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| EA201890790A1 (ru) * | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
| PL3368572T3 (pl) | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| CR20180151A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Antcuierpos anti-pd1 y métodos de uso |
| KR102809728B1 (ko) | 2015-12-02 | 2025-05-21 | 주식회사 에스티큐브 | 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법 |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
-
2019
- 2019-02-18 AR ARP190100406A patent/AR114127A1/es unknown
- 2019-02-18 TW TW108105310A patent/TWI708787B/zh active
- 2019-02-22 PE PE2020001188A patent/PE20210045A1/es unknown
- 2019-02-22 KR KR1020207024945A patent/KR102536014B1/ko active Active
- 2019-02-22 SG SG11202008437WA patent/SG11202008437WA/en unknown
- 2019-02-22 CA CA3092064A patent/CA3092064C/en active Active
- 2019-02-22 JO JOP/2020/0210A patent/JOP20200210A1/ar unknown
- 2019-02-22 CR CR20200375A patent/CR20200375A/es unknown
- 2019-02-22 MA MA052414A patent/MA52414A/fr unknown
- 2019-02-22 CN CN201980016779.7A patent/CN111886253B/zh active Active
- 2019-02-22 KR KR1020237017035A patent/KR20230079458A/ko not_active Withdrawn
- 2019-02-22 AU AU2019228474A patent/AU2019228474B2/en active Active
- 2019-02-22 CN CN202411106932.4A patent/CN118903407A/zh active Pending
- 2019-02-22 MX MX2020009124A patent/MX2020009124A/es unknown
- 2019-02-22 BR BR112020015983-2A patent/BR112020015983A2/pt not_active Application Discontinuation
- 2019-02-22 EA EA202091809A patent/EA202091809A1/ru unknown
- 2019-02-22 JP JP2020545727A patent/JP7071521B2/ja active Active
- 2019-02-22 CN CN202411106937.7A patent/CN118846042A/zh active Pending
- 2019-02-22 EP EP19709336.2A patent/EP3759139A1/en active Pending
- 2019-02-22 US US16/282,609 patent/US10493148B2/en active Active
- 2019-02-22 WO PCT/US2019/019076 patent/WO2019168745A1/en not_active Ceased
- 2019-02-22 CN CN202411106929.2A patent/CN118806891A/zh active Pending
-
2020
- 2020-07-24 ZA ZA2020/04601A patent/ZA202004601B/en unknown
- 2020-07-28 IL IL276340A patent/IL276340A/en unknown
- 2020-08-05 DO DO2020000153A patent/DOP2020000153A/es unknown
- 2020-08-19 CO CONC2020/0010188A patent/CO2020010188A2/es unknown
- 2020-08-24 CL CL2020002180A patent/CL2020002180A1/es unknown
- 2020-09-01 EC ECSENADI202053544A patent/ECSP20053544A/es unknown
- 2020-09-01 PH PH12020551463A patent/PH12020551463A1/en unknown
- 2020-09-02 SA SA520420082A patent/SA520420082B1/ar unknown
-
2022
- 2022-03-07 JP JP2022034413A patent/JP7259107B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061724A patent/JP2023093549A/ja active Pending
- 2023-07-10 AU AU2023204569A patent/AU2023204569A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088411A5 (https=) | ||
| NZ622583A (en) | Protein formulations and methods of making same | |
| JP2018108086A5 (https=) | ||
| RU2011110169A (ru) | Антитела против ccr2 | |
| JP2016538876A5 (https=) | ||
| JP2020528768A5 (https=) | ||
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| CO6690799A2 (es) | Composiciones de anticuerpo anti - cmv y métodos de uso | |
| JP2017536102A5 (https=) | ||
| RU2511410C3 (ru) | АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2022141959A5 (https=) | ||
| TW202214697A (zh) | 抗ｃｄ７０抗體及其應用 | |
| HRP20251165T1 (hr) | Proteini koji vežu antigene koji antagoniziraju leptinski receptor | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| DE60114829T2 (de) | Variable region des monoklonalen antikörpers gegen das hbv s-oberflächenantigen und für diese kodierendes gen | |
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| CN111620944A (zh) | 一种全人源化抗乙肝病毒单克隆抗体、制备方法及其应用 | |
| MX384745B (es) | Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. | |
| TH2001004888A (th) | Pd-1 อะโกนิสต์แอนติบอดีและการใช้ของสิ่งดังกล่าว | |
| NZ766604B2 (en) | Pd-1 agonist antibodies and uses thereof | |
| NZ766604A (en) | Pd-1 agonist antibodies and uses thereof | |
| CN111450248B (zh) | 一种用于预防和治疗prrsv感染的抗体药物 | |
| CN111471104A (zh) | 一种prrsv广谱中和单克隆抗体及其应用 |